Geron Corporation announced the appointment of Gaurav Aggarwal, M.D., to the Company?s Board of Directors. Dr. Aggarwal has been a prominent investor in the life sciences sector for more than two decades and has a history of expertise in financial and corporate strategy, as well as business development, in companies with which he has been affiliated at both an operational and board level. Dr. Aggarwal most recently served as Managing Director of Vivo Capital LLC, a global investment firm from 2016 to 2023, and Chief Investment Officer of its US public investment fund, from 2021 to 2023.

Previously, heserved as the Chief Business Officer of Ocera Therapeutics Inc., a publicly traded clinical-stage company developing therapies for orphan liver conditions, from April 2014 through October 2016; as Managing Director of Investor Growth Capital from January 2013 through December 2013; and as a General Partner at Panorama Capital, L.P., a venture capitalfund, from August 2006 through December 2012. Earlier in his career, Dr. Aggarwal was an associate with JPMorgan Partners, LLC, a private equity division of JPMorgan Chase & Co. Dr. Aggarwal has served on the board of directors of Unicycive Therapeutics Inc. since March 2023, and previously served on the boards of directors of Sierra Oncology Inc. (acquired by GlaxoSmithKline plc), Hyperion Therapeutics Inc. (acquired by Horizon Pharma plc), and on several privately held biopharmaceutical companies.

Dr. Aggarwal received his MD from Columbia University, College of Physicians & Surgeons, and his BS in Agricultural Economics from Cornell University.